Comparing BioMarin Pharmaceutical (NASDAQ:BMRN) & Contineum Therapeutics (NASDAQ:CTNM)

BioMarin Pharmaceutical (NASDAQ:BMRN) and Contineum Therapeutics (NASDAQ:CTNM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Earnings and Valuation

This table compares BioMarin Pharmaceutical and Contineum Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.09 billion	3.42	$426.86 million	$2.66	20.69
Contineum Therapeutics	$50.00 million	6.41	-$42.26 million	($2.25)	-4.88

BioMarin Pharmaceutical has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for BioMarin Pharmaceutical and Contineum Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1	6	16	0	2.65
Contineum Therapeutics	1	0	6	1	2.88

BioMarin Pharmaceutical presently has a consensus target price of $89.91, suggesting a potential upside of 63.38%. Contineum Therapeutics has a consensus target price of $20.40, suggesting a potential upside of 85.62%. Given Contineum Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than BioMarin Pharmaceutical.

Volatility & Risk

BioMarin Pharmaceutical has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.

Institutional & Insider Ownership

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.9% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 11.3% of Contineum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares BioMarin Pharmaceutical and Contineum Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	16.82%	9.53%	7.68%
Contineum Therapeutics	N/A	-32.33%	-30.27%

Summary

BioMarin Pharmaceutical beats Contineum Therapeutics on 9 of the 15 factors compared between the two stocks.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

About Contineum Therapeutics

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.